Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Overactive Detrusor, Neurogenic Bladder
Interventions: Oxybutynin, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 16 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 10
States / cities: Loma Linda, California • Orange, California • Aurora, Colorado + 7 more

Conditions: Hematologic Malignancies
Interventions: Venetoclax, ethinyl estradiol/levonorgestrel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 3
States / cities: Detroit, Michigan • Lebanon, New Hampshire • Canton, Ohio

Conditions: Social Anxiety Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: The Medical Research Network; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar I Disorder
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Costa Mesa, California • Cromwell, Connecticut • Doral, Florida + 5 more

Conditions: Headache, Migraine
Interventions: Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy]; Drug
Lead sponsor: Chicago Headache Center & Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois • Naperville, Illinois

Conditions: Platysma Prominence
Interventions: OnabotulinumtoxinA, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Vista, California + 16 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: Obinutuzumab, Bendamustine, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 15
States / cities: Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more

Conditions: Cystic Fibrosis, Chronic Pancreatitis
Interventions: CREON; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more

Conditions: Healthy Volunteer
Interventions: [14C] ABBV-CLS-7262; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Rheumatoid Arthritis (RA)
Interventions: Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 44
States / cities: Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more

Conditions: Cystic Fibrosis (CF)
Interventions: ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 22
States / cities: Mobile, Alabama • Los Angeles, California • Ventura, California + 19 more

Conditions: Acute Pancreatitis
Interventions: No intervention, this is an observational study; Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Baltimore, Maryland • Columbus, Ohio • Pittsburgh, Pennsylvania

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Cariprazine Versus Placebo for Social Anxiety Disorder

Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting

Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Post Acute Pancreatitis Pancreatic Exocrine Insufficiency

About this AbbVie sponsor directory page